

## **IN THE CLAIMS**

Please cancel claims 1-9, 12-26 and 28-62 without prejudice.

Please add new claim 63.

- 1-9. (Cancelled)
- 10. (Original) A bispecific antibody with binding specificity for a first epitope and a second epitope, wherein the first epitope is the epitope bound by the monospecific antibody of claim 1.
- 11. (Original) The bispecific antibody of claim 10, wherein the second epitope is an epitope of seprase, an epitope of MT1-MMP, an epitope of MMP-2 or an epitope of  $\alpha(3)\beta(1)$ -integrin.
- 12-26. (Cancelled)
- 27. (Original) A pharmaceutical composition for inhibiting angiogenesis comprising an effective amount of a bispecific antibody according to claim 10 and a pharmaceutically acceptable carrier.
- 28-62. (Cancelled)
- 63. (New) A pharmaceutical composition for inhibiting cancer invasion comprising an effective amount of a bispecific antibody according to claim 10 and a pharmaceutically acceptable carrier.